Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06880042

COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO

Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Vitiligo - Macular Depigmentation Hypopigmentation Pigmentation Disorders Skin Diseases Skin and Connective Tissue Diseases Tacrolimus Vitiligo

Age range

15 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Lahore general.hospital

Lahore, Punjab Province, Pakistan

About this study

Evaulation of efficacy and safety of narrowband uvb and tacrolimus and NBUVB and calcipotriol in patient if stable vitiligo with body surface area less than 20% It will be assessed by VASI score and VIisual analogie scale

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Localized vitiligo Age 15 to 70years Body surface upto 20% Stable more than 3 months

Exclusion criteria

  • • Pregnant or lactating female patients.
  • Skin malignancy or any other malignant skin condition.
  • Photo induced or photo aggravated dermatosis like (SLE, photodermatitis, rosacea, psoriasis, pemphigus vulgaris) along with vitiligo.
  • Prior history of allergy to tacrolimus or calcipotriol.
  • Other form of treatment for vitiligo within at least 1 month.

Treatment and study plan

Tacrolimus

Drug

Tacrolimus is calcineurin inhibitor that will act as immunomodulator

Calcipotriol

Drug

Calcipotriol is a vitamin D analogue that will act as immunomodulator

Primary outcomes

  1. VASI improvement upto 50%

    Time frame: 3 months

    Improvement in VASI score upto 50%

Sponsors and collaborators

Lead sponsor

Dr ayesha wahid

Other Gov

Registry information

Acronym: NB-UVB

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Mar 17, 2025
Registry last updated
Jun 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.